Seegene, a maker of COVID-19 test kits, had stocks increase by 919 percent by August. The founder of Alteogen, a biotech that produces subcutaneous needles, became a billionaire after the company’s stocks surged last year. After the vaccine rollout, their founders are no longer billionaires as their stocks sank more than 41 percent, according to the Bloomberg Billionaires Index.
Glove-makers in Malaysia noted five billionaires by August last year. Since then, their shares are down 40 percent from previous highs, wiping $9 billion from their founders’ net worth, Fortune reports.
“The extravagant rise in stock prices is going to be far-fetched, and it’s unlikely they’ll grow at the same rate,” Nirgunan Tiruchelvam, head of consumer sector equity research at Tellimer, told Fortune. “We’re going to see a rotation from virus stocks to vaccine stocks.”
More articles on leadership and management:
Unemployment claims fall to 730,000 after 6-week high
Michigan hospital CEO remembered for his natural leadership abilities, honesty
Children’s Minnesota appoints most diverse board to date
At Becker's 4th Annual CEO + CFO Roundtable, taking place November 2–5 in Chicago, more than 1,500 hospital and health system executives tackle decisions that determine whether organizations thrive or merely survive: protecting margins under cost pressure, choosing where to grow, renegotiating payer relationships, stabilizing the workforce and proving real ROI on technology. This is where leaders work through them together, face-to-face. Apply for complimentary registration now.
